We propose that the research community that is focused on the regulatory role of IKKα in various cancers, cardiovascular conditions, and inflammatory-based diseases can gain a greater understanding of the NF-kB signalling pathways using these pharmacological agents. This evidence concerns the gene NFKB1 and cancer.